Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | DRD5 | P21918 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358 | 0.91 | HRH3 (0.41) | HRH3CA12CA2CA9DRD2 | |
| SCHEMBL2729745 | 0.91 | HRH3 (0.41) | HRH3CA12CA2CA9DRD2 | |
| SCHEMBL21224483 | 0.91 | HRH3 (0.41) | HRH3CA12CA2CA9DRD2 | |
| Trimethylammonium SCHEMBL28069178 | 0.89 | KCNH2 (0.34) | HRH3CA12CA2CA9DRD2 | |
| Iodide SCHEMBL1758226 | 0.87 | HRH3 (0.39) | HRH3CA12CA2CA9DRD2 | |
| SCHEMBL10948053 | 0.87 | HRH3 (0.39) | HRH3CA12CA2CA9DRD2 | |
| Fluoride SCHEMBL64252 | 0.87 | HRH3 (0.39) | HRH3CA12CA2CA9DRD2 | |
| SCHEMBL756023 | 0.87 | HRH3 (0.39) | HRH3CA12CA2CA9DRD2 | |
| Hydrochloric Acid SCHEMBL210163 | 0.87 | HRH3 (0.39) | HRH3CA12CA2CA9DRD2 | |
| SCHEMBL14270553 | 0.87 | HRH3 (0.39) | HRH3CA12CA2CA9DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5487954-A | Non-acicular modified high coercivity iron oxides for high density magnetic recording and the processes of making the same | NATIONAL SCIENCE COUNCIL (TW) | 1996-01-30 | — | — | US | claimed |
| US-20240239799-A1 | (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2024-07-18 | — | — | US | disclosed |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240208979-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240207265-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4376843-A1 | TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR | Cyclerion Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4373933-A1 | BETA-CATENIN (CTNNB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-113677680-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4358957-A1 | (1H-PYRROLO[2,3-B]PYRIDIN-1-YL)PYRIMIDIN-2-YL-AMINO-PHENYL--ACRYLAMIDE INHIBITORS OF EGFR FOR USE IN THE TREATMENT OF BRAIN TUMORS | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2003049678-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003048136-A1 | CYCLOPROPYL HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003039460-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003035619-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035616-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035615-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035614-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003024969-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-6310233-B1 | ESPECIALLY REACTING TEREPHTHALIC ACID WITH ETHYLENE OXIDE TO PRODUCE MONO- AND BISHYDROXYETHYL ESTER MONOMERS; MOLE RATIO OF MONOHYDROXYALKYL ESTER MONOMER TO BISHYDROXYALKYL ESTER MONOMER IS GREATER THAN ABOUT 0.3; MINOR AMOUNTS OF OLIGOMERS | ARTEVA NORTH AMERICA S.A.R.L. (CH) | 2001-10-30 | — | — | US | disclosed |
| EP-0999201-A1 | Pressure ethoxylation in dense gases to produce hydroxyalkyl ester monomer | ARTEVA TECHNOLOGIES S.à.r.l. (CH) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208979-A1 | sGC STIMULATORS | GMPS, PRKG1, CGAS | HRH3 4542/4885CA12 3944/4885CA2 646/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | HRH3 2270/4885CA12 2122/4885CA2 1565/4885 |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | P2RY1, P2RY11, GMPS | HRH3 2129/4885CA12 4220/4885CA2 1642/4885 |
| US-20240239799-A1 | (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER | PTPN1, PTPN5, PTPRJ | HRH3 862/4885CA12 4690/4885CA2 2890/4885 |
| US-20240207265-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1A1, GUCY1B2 | HRH3 3077/4885CA12 2324/4885CA2 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.